Complementary therapy for atopic eczema and other allergic skin diseases

Dermatologic Therapy

Volumn 16, Issue 2, 2003, Pages 150-163

  Artik, Suzan ^a   Ruzicka, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Atopic eczema; Conventional therapy; Unconventional therapy

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ARNICA MONTANA EXTRACT; BUFEXAMAC; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLEMATIS ARMANDII EXTRACT; CYCLOSPORIN; CYCLOSPORIN A; DICTAMNUS DASYCARPUS EXTRACT; ERYTHROMYCIN; GLUCOCORTICOID; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; IMMUNOMODULATING AGENT; LEDEBOURIELLA SASELOIDES EXTRACT; LOPHATERUM GRACILE EXTRACT; MACROLIDE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PIMECROLIMUS; PONIA LACTIFLORA EXTRACT; POTENTILLA CHINENSIS EXTRACT; PSORALEN; REHMANNIA GLUTINOSA EXTRACT; SCHIZONEPETA TENUIFOLIA EXTRACT; TACROLIMUS; TRIBULUS TERRESTRIS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARNICA MONTANA; ATOPIC DERMATITIS; CHINESE MEDICINE; CLEMATIS ARMANDII; DICTAMNUS DASYCARPUS; DRUG MECHANISM; GINGIVA HYPERPLASIA; GLYCYRRHIZA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEDEBOURIELLA SASELOIDES; LOPHATHERUM GRACILE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PHOTOTOXICITY; PHYTOTHERAPY; PONIA LACTIFLORA; POTENTILLA CHINENSIS; PUVA; QUALITY OF LIFE; REHMANNIA GLUTINOSA; REVIEW; SCHIZONEPETA TENUIFOLIA; SEDATION; SKIN ALLERGY; SKIN CARCINOMA; SKIN INFECTION; SKIN PENETRATION; TREMOR; TRIBULUS TERRESTRIS; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION;

ADJUVANTS, IMMUNOLOGIC; DERMATITIS, ATOPIC; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; TACROLIMUS;

EID: 0041671026     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2003.01624.x     Document Type: Review

References (87)

1. Rothe MJ, Grant-Kels JM. Atopic dermatitis: an update. J Am Acad Dermatol 1996: 35: 1-13.
2. Ruzicka T, Ring J, Przybilla B. Handbook of atopic eczema. Heidelberg, Germany: Springer Verlag, 1991.
3. Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 1999: 83: 464-470.
4. Ruzicka T. Atopic eczema between rationality and irrationality. Arch Dermatol 1998: 134: 1462-1469.
5. Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy in Guinea-Bissau. Lancet 1996: 347: 1792-1796.
6. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997: 275: 77-79.
7. Matricardi PM, Rosmini F, Riondino S, et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000: 320: 412-417.
8. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001: 357: 1076-1079.
9. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vacc suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001: 107: 531-534.
10. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994: 102: 128-137.
11. Leung DYM. Immunopathology of atopic dermatitis. Springer Semin Immunopathol 1992: 13: 427-440.
12. Leung DYM. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995: 96: 302-319.
13. Wüthrich B. Neurodermitis atopica sive constitutionalis. Ein pathogenetisches Modell aus der Sicht des Allergologen. Acta Dermatol 1983: 9: 1-7.
14. Grewe M, Walther S, Gyufko K, Czech W, Schöpf E, Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995: 105: 407-410.
15. Young E, Patel S, Stoneham M, et al. The prevalence of reaction to food additives in a survey population. J R Coll Physicians Lond 1987: 21: 241-247.
16. Neuber K, Koenig W, Ring J. Staphylococcus aureus und atopisches Ekzem. Hautarzt 1993: 44: 135-142.
17. Przybilla B, Eberlein-Konig B, Rueff F. Practical management of atopic eczema. Lancet 1994: 343: 1342-1345.
18. Resano A, Crespo E, Fernandez-Benitez M, Sanz ML. Atopic dermatitis and food allergy. J Invest Allergol Clin Immunol 1998: 8: 271-276.
19. Przybilla B, Ring J. Food allergy and atopic eczema. Semin Dermatol 1990: 9: 220-225.
20. Fuglsang G, Msen C, Halken S, Jorgensen M, Ostergaard PA, Osterballe O. Adverse reaction to food additives in children with atopic symptoms. Allergy 1994: 49: 117-132.
21. Gutgesell C, Schäkel K, Fuchs T, Neumann C. Nahrungsmitteladditiva sind kein Schubfaktor der atopischen Dermatitis bei Erwachsenen. Allergologie 1997: 20: 519-521.
22. Krutmann J. Phototherapy for atopic dermatitis. Dermatol Ther 1996: 1: 24-31.
23. Kirby B, Chalmers RJ. Multiple squamous cell carcinomas following photochemotherapy for atopic eczema. Clin Exp Dermatol 1999: 24: 337.
24. Grundmann-Kollmann M, Behrens S, Podda M, Peter RU, Kaufmann R, Kerscher M. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999: 40: 995-997.
25. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000: 25: 552-558.
26. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis, results of a multicenter trial. J Am Acad Dermatol 1998: 38: 589-593.
27. Grabbe J, Welker P, Humke S, et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 1996: 107: 419-422.
28. Dittmar HC, Pflieger D, Schopf E, Simon JC. UVA1-phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis. Hautarzt 2001: 52: 423-427.
29. Tzaneva S, Seeber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001: 45: 503-507.
30. Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000: 42: 254-257.
31. Richter HI, Billmann-Eberwein C, Grewe M, et al. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 1998: 38: 585-588.
32. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000: 1: 41-46.
33. Kagi M, Zurbriggen B, Burg G, Wüthrich B. Treatment of atopic dermatitis with a new galenical formulation of cyclosporine A (Neoral): monitoring the clinical activity with serological parameters. Dermatology 1996: 193: 163-168.
34. Zoneveld IM, de Rie MA, Bejaards RC, et al. The long-term safety and efficacy of cyclosporine in severe refractory atopic dermatitis: a comparison of two doses regimes. Br J Dermatol 1996: 135: 15-20.
35. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996: 34: 1016-1021.
36. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997: 337: 816-821.
37. Hanifin JM, Tacrolimus Ointment Study Group. Use of tacrolimus ointment in 3-6-year-olds with severe atopic dermatitis: a dose escalation study. J Invest Dermatol 1998: 110: 681.
38. Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2001: 2: 1167-1175.
39. Reitamo S, Wollenberg A, Schoepf E, et al. Safety and efficacy of 1 year tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000: 136: 999-1006.
40. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM, Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001: 44: 58-64.
41. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002: 109: 547-554.
42. Van Leent EJM, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002: 204: 63-68.
43. Jensen P. Use of alternative medicine by patients with atopic dermatitis and psoriasis. Acta Derm Venereol 1990: 70: 421-424.
44. Triebskorn A, Drosner M. Methods of alternative medicine treatment assessed by patients with allergies and patients with chronic skin diseases. Z Hautkr 1989: 64: 487-494.
45. Jensen P. Alternative therapy for atopic dermatitis and psoriasis: patient-reported motivation, information source and effect. Acta Derm Venereol 1990: 70: 425-428.
46. Zschocke I, Stein B, Tanno S, Beckmann S, Augustin M. Psychosocial characterization of patients with atopic dermatitis in conventional versus alternative-medical therapy. Forsch Komplementarmed 1999: 6: 22-25.
47. Sheehan MP, Atheron DJ. A control trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992: 126: 179-184.
48. Sheehan MP, Rustin MHA, Atherton DJ, Buckley C. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992: 340: 13-17.
49. Latchman Y, Whittle B, Rustin MHA, Atherton DJ, Brostoff J. The efficacy of traditional Chinese herbal therapy in atopic eczema. Int Arch Allergy Immunol 1994: 104: 222-226.
50. Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 1998: 134: 1388-1393.
51. Ferguson JE, Chalmers RJG, Rowlands DJ. Reversible dilated cardiomyopathy following treatment of atopic eczema with Chinese herbal medicine. Br J Dermatol 1997: 136: 592-593.
52. Perharic-Walton L, Murray V. Toxicity of Chinese herbal remedies. Lancet 1992: 340: 673-674.
53. Wang LX, Lu LZ. Analysis of 162 reported cases of side effects of Chinese medical material. J Beijing Clin Pharm 1992: 5: 50-55.
54. Shiota Y, Wilson JG, Matsumoto H, et al. Adult respiratory distress syndrome induced by a Chinese medicine, Kamisyoyo-San. Intern Med 1996: 35: 494-496.
55. Mostefa-Kara N, Pauels A, Pines E, Biour M, Levy VG. Fatal hepatitis after herbal tea. Lancet 1992: 340: 674.
56. Chan TYK, Chan JCN, Tomlinson B, Critchley JAJH. Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 1993: 32: 1532-1534.
57. Edwards CRW. Lessons from licorice. N Engl J Med 1991: 325: 1223-1227.
58. Sheehan MP, Atherton DJ. One year follow-up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994: 130: 488-493.
59. Sheehan MP, Stevens H, Osterele LSD, Atherton DJ. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for one year. Clin Exp Dermatol 1995: 20: 136-140.
60. Bedi MK, Shenefelt PD. Herbal therapy in dermatology. Arch Dermatol 2002: 138: 232-242.
61. Xu XJ, Banerjee P, Rustin MH, Poulter LW. Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema. Br J Dermatol 1997: 136: 54-59.
62. Latchman Y, Banerjee P, Poulter LW, Rustin MH. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol 1996: 109: 243-249.
63. Fung AY, Look PC, Chong LY, But PP. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol 1999: 38: 387-392.
64. Matsumoto T, Ischida M, Hatta T, et al. Inhibitory effects of Sho-seiryu-to on histamine release and degranulation from rat mast cells. ORL Tokyo 1991: 34: 289-293.
65. Shichinohe K, Shimuzu M, Kuokawa K. Effect of M-711 on experimental skin reactions induced by chemical mediators in rats. J Vet Med Sci 1996: 58: 419-423.
66. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an antiinflammatory sesquiterpene lactone from arnica, selectively inhibits transcription factor NF-κB. Biol Chem 1997: 378: 951-961.
67. Melnik BC, Plewig G. Is the origin of atopic dermatitis linked to the deficient conversion of w-6-fatty acids to prostaglandin E? J Am Acad Dermatol 1989: 21: 557-563.
68. Biagi P, Hrelia S, Celon M, et al. Erythrocyte membrane fatty acid composition in children with atopic dermatitis compared to aged-matched controls. Acta Paediatr 1993: 82: 789-790.
69. Wright S, Sanders T. Adipose tissue essential fatty acids in the plasma phospholipids of patients with atopic eczema. Br J Dermatol 1991: 110: 643-648.
70. Levin C, Maibach H. Exploration of "alternative" and "natural" drugs in dermatology. Arch Dermatol 2002: 138: 207-211.
71. Andreassi M, Forleo P, Di Lorio A, Masci S, Abate G, Amerio P. Efficacy of γ-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res 1997: 25: 266-274.
72. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. Drug Res 1999: 49: 635-642.
73. Worm M, Henz BM. Novel unconventional therapeutic approaches to atopic eczema. Dermatology 2000: 201: 191-195.
74. Berth-Jones J, Graham Brown RAC. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993: 341: 1557-1560.
75. Soyland E, Funk J, Rajka G, Sandberg M. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis: a double-blind, multicentre study. Br J Dermatol 1994: 130: 757-764.
76. Borrek S, Hildebrandt A, Forster J. Gamma-linoleic-acid-rich borage seed oil capsules in children with atopic dermatitis: a placebo-controlled double-blind study. Klin Pädiatr 1997: 209: 100-104.
77. Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. Arch Dis Child 1996: 75: 494-497.
78. Wahn U, Staab D, Nilsson L. Atopic eczema: how to tackle the most common atopic symptom. Pediatr Allergy Immunol 1999: 10: 19-23.
79. Miller LG. Herbal medicinals. Arch Intern Med 1998: 158: 2200-2208.
80. Schoni MH, Nicolaizik WH, Schoni-Affofter F. Efficacy trial of bioresonance in children with atopic dermatitis. Int Arch Allergy Immunol 1997: 112: 238-246.
81. Shenefelt PD. Hypnosis in dermatology. Arch Dermatol 2000: 136: 393-399.
82. Kay AB, Lessof MH. Allergy. Conventional and alternative concepts. A report of the Royal College of Physicians Committee on Clinical Immunology and Allergy. Clin Exp Allergy 1992: 22: 1-44.
83. Saarinen UM, Kajosnaari U. Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Lancet 1995: 346: 1065-1069.
84. Chan YH, Shek LP, Aw M, Quak SH, Lee BW. Use of hypoallergenic formula in the prevention of atopic disease among Asian children. Paediatr Child Health 2002: 38: 84-88.
85. Stangier U, Ehlers A, Gieler U. Verhaltenstherapie und Patientenschulung bei erwachsenen Neurodermitis-Patienten. In: Petermann F, ed. Asthma und Allergie: Verhaltensmedizinische Grundlagen und Anwendungen. Goettingen: Hogrefe, 1995.
86. Gieler U, Ehlers A, Höhler T, Burkhard G. Die psychosoziale Situation der Patienten mit endogenem Ekzem. Hautarzt 1990: 41: 416-423.
87. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. Effekte kombinierter therapeutischer Maßnahmen bei Patienten mit Psoriasis und atopischer Dermatitis. Hautarzt 1999: 50: 791-797.